Low 21-gene expression score associated with low risk of breast cancer recurrence
the ONA take:
Patients with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer and a favorable 21-gene expression assay score had very low rates of disease recurrence at 5 years with endocrine therapy alone, initial results of the TAILORx study published online ahead of print in The New England Journal of Medicine have shown.
For the study, 10,253 eligible women with breast cancer were enrolled. Of those, 1,626 women had a recurrence score of 0 to 10 who were assigned to receive endocrine therapy alone without chemotherapy.
Results showed that 5-year invasive disease-free survival rate was 93.8% (95% CI: 92.4, 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI: 98.7, 99.6), and the rate of freedom from recurrence at a distant or local-regional site was 98.7%. Researchers found that the overall survival rate was 98.0% (95% CI: 97.1, 98.6).
"The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice," said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.
Patients with HER2-negative, axillary node-negative breast cancer and favorable 21-gene expression assay score had low rates of recurrence.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|